Prothrombotic Activity of Oral Contraceptives in Patients With Congenital Thrombophilia Varies With the Defect
The relationship between oral contraceptive therapy (OCT) and venous thrombosis has drawn considerable attention during the past two decades (1) (2) (3) (4) . This relationship is seen not only in healthy women, but especially in women with a prothrombotic diathesis (5,6).
Because of this observation, we have read with interest the paper by Mira et al. on the OCT-associated or OCTinduced venous thrombosis in a group of patients with different defects (7). Because we have had the opportunity to study the matter extensively during the past 10 years, we take the liberty of making a few comments (5,6,8-10).
Of 36 cases presented, 16 patients had a congenital prothrombotic defect, whereas 20 patients showed no coagulation abnormality. Five of the patients with con-' genital defects also had one or two associated acquired conditions. Six healthy subjects also had at least one associated risk factor. OCT as a cause for deep vein thrombosis (DVT) is usually measured by two parameters : 1) the prevalence of patients on OCT who develop DVT in comparison with a group of people not on OCT and 2) the demonstration of an early appearance of DVT in thrombophilic women on OCT in comparison with healthy women always on OCT. This has been demonstrated to be so by us a few years ago (6,9). Unfortunately, we cannot gather any information with regard to the prevalence of venous thrombosis observed in the patients presented versus a control group. In f~ct, no such information is supplied in the paper. On the contrary, some data may be gathered regarding the time of occurrence of the thrombotic phenomena. We have made some calculations from the data supplied in Table 1 .
The average number of cycles of patients with coagulation defects was approximately 17. If one excludes the patient with protein S defect who developed thrombosis after 84 cycles, one reaches the value of approximately 12 cycles. These data are not different from those results seen in . healthy subjects (approximately 15 cycles). Patients with associated risk factors have been excluded from the calculation. However, even including the patients with associated risk factors, the average number of cycles before the appearance of the thrombotic phenomenon did not change considerably in the two groups. This finding could indicate that the clotting defect had very little or no impact on the time of occurrence of venous thrombosis. In fact, the figures could indicate that the presence of a defect somehow protected the patient from the occurrence of thrombotic phenomena, an untenable assumption. The results previously outlined can be interpreted only by admitting that the d~fe~ts .bein~ considered are considerably different among themselves. If one limits the calculations to the most severe defects (AT [antithrombin], protein C, protein S) and excludes the patient with protein S deficiency who developed thrombosis after 84 cycles, one obtains 'an average value of approximately 5 cycles, a value in agreement with the results i presented by us ~(b,9). This distinction is absolutely nec-/ essary; otherwise, we risk missing the most important : point, namely that clotting factor defects are different in severity and therefore may be differently influenced by / the intake of oral contraceptive therapy. In Table 1 , we 'i summarize the results obtained by us in recent years. / These data clearly indicate that the pattern varies from / defect to defect. Antithrombin deficiency is by far the / most severe condition. / Women with this defect may develop a DVT after or j 2 cycles of OCT, even in the absence of associated con-! ' & d q u o ;
ditions. Protein C and protein S defects are sc~mewhat ; less severe. As far as the factor V (FV) Leiden defect a is concerned, homozygotcs and h~t~rc~ry~~t~s show a i similar increase in prevalence, although hoinozygotes I appear to develop thrombosis after a shorter number of / cyclcs. This finding is in agreement with the current & d q u o ; opinion that maintains that the FV Leiden polymorphism i is a mild defect ( 1 I ~. However, not all problems are , solved l2). For example, it remains to be explained why some patients, even if affected by severe conditions, may remain asymptomatic.
We disagree with the recommendations made regarding pretreatment screening. It is important to rule out AT, ; protein C, and protein S defects. It is true that these defects are not as frequent as FV Leiden, but they are more severe ( I 1,1;3~. Homozygous and pseudohomozy-I gous patients with FV Leiden should probably be advised to abstain from taking oral contraceptives. It is still questionable if heterozygous FV Leiden patients show an absolute contraindication to OCT. Because the thrombotic phenomenon appears to occur after a large number ! of cycles (approximately 14), short periods of OCT, if & d q u o ; necessary because of important conditions (endometriosis, absolute need to avoid pregnancy for previous child with mongolism, intrauterine device intolerance, etc.), could be at least tentatively considered. Single patients with the clotting defect mentioned previously (APC resistance) should be carefully evaluated because of the ; slightly increased risk of thrombosis as compared to j healthy women.
We do not take into consideration the G to A 20210 prothrombin abnormality, because it is not certain wheth- 
